Waltham, Mass.-based Deciphera Pharmaceuticals Inc.'s updated results from its phase I trial with DCC-2618, a broad-spectrum KIT and platelet-derived growth factor receptor (PDGFR) alpha inhibitor, in patients with gastrointestinal stromal tumors (GIST) at the American Society of Clinical Oncology (ASCO) meeting cheered investors.